Darunavir: Difference between revisions
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Darunavir, better known as Prezista, (3eky)"/> ===Better Known as: Prezista=== * Marketed... |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | * Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 2006 ( | * Date of FDA Approval (Patent Expiration): 2006 (2012) <br /> | ||
* 2009 Sales: | * 2009 Sales: $590 Million | ||
* Importance: It is the Office of AIDS Research Advisory Council recommended treatment. It was designed to work against [[HIV Protease]] Inhibitor resistant strains of HIV and also has a reduced side effect profile compared to older treatments like [[Indinavir]].<ref>PMID:17900913</ref> | * Importance: It is the Office of AIDS Research Advisory Council recommended treatment. It was designed to work against [[HIV Protease]] Inhibitor resistant strains of HIV and also has a reduced side effect profile compared to older treatments like [[Indinavir]].<ref>PMID:17900913</ref> Performed better than [[Kaletra]] in clinical trials. <ref>http://www.reuters.com/article/idUSN18430962</ref> | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||